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Abstract
Background: Vitamin D supplementation in childhood improves the achievement of peak bone mass. We investigated the
effect of supplementation with calcitriol on bone turnover in recent-onset type 1 diabetes (T1D). Moreover, the association
between osteocalcin and parameters of b-cell function and metabolic control was examined.
Methodology/Principal Findings: We conducted a post-hoc analysis of a double-blind, placebo-controlled study of
calcitriol supplementation to preserve b-cell function. 27 recent-onset T1D subjects, mean age 22 years, were randomized to
0.25 mg calcitriol per day or placebo (1:1) and followed up for one year. Changes in bone formation (osteoclacin) and
resorption (beta-CrossLaps) markers, and differences between placebo and calcitriol-treated group were evaluated. At
baseline, osteocalcin levels were significantly lower in female than in male patients (P,0.01) while no other metabolic
parameters as HbA1c and C-peptide differed between gender. No significant correlations were found in relation to HbA1c,
insulin requirement and C-peptide. At 1 year follow-up, no significant differences were observed between calcitriol and
placebo groups for osteocalcin and b-CrossLaps. In the placebo group osteocalcin levels were unrelated with parameters of
metabolic control, such as C-peptide, insulin requirement or HbA1c. Changes of C-peptide, insulin requirement and HbA1c
were not related to osteocalcin levels.
Conclusions: Supplementation with 0.25 mg calcitriol per day to patients with new-onset T1D does not affect circulating
markers of bone turnover. OC levels were unrelated to b-cell function and other metabolic parameters suggesting that OC is
ineffective to control pancreatic function in presence of aggressive autoimmune destruction.
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Introduction
In 1948 Albright et al. investigated bone development in
diabetic children linking for the first time diabetes with bone
mass loss [1]. Since then several studies have examined the
relationship between type 1 diabetes (T1D) and skeletal disorders
showing an impaired peak of bone mass and, consequently, an
increased risk of osteoporosis and fractures [2,3]. A large variety of
mechanisms have been proposed to explain this finding, (such as
hyperglycemia, inflammation and generation of advanced-glyca-
tion end products into the bone matrix), but most studies have
focused on the lack of anabolic effect of insulin on osteoblasts,
indicating T1D as a condition of low bone turnover, meaning both
osteoblast and osteoclast functions are suppressed [4,5,6].
Vitamin D deficiency has been associated with T1D [7] and
several studies suggest that vitamin D may exert immunomodu-
latory effects. [7,8]. At high doses calcitriol prevents insulitis and
the development of experimental diabetes, by acting on the
defective suppressor cellular function, or cytokine expression
modulation [7,9]. Moreover, supplementation with vitamin D
during early childhood may decrease the risk of developing T1D
[10,11]. Contrary to what was expected, we have found that
calcitriol supplementation is not effective in improving b-cell
function or reducing insulin requirement in patients with newly
diagnosed T1D [12].
However, a large amount of data suggests the importance of
vitamin D to preserve bone accrual in young subjects [13,14].
Vitamin D supplementation in deficient children and adolescents
restores mineralization and may improve bone health in deficient
children and adolescents [15]. The beneficial effect of vitamin D is
even more pronounced when supplementation starts in infancy or
at the beginning of the adolescence [16,17], and seems to be
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primarily dependent on a reduction of bone resorption [18]. The
achievement of peak of bone mass plays a major role in
determining bone health throughout life. A 10% rise in bone
mass during adolescence or early adulthood can halve the risk of
an osteoporotic fracture in older age [19].
Nevertheless, according to our previous study, vitamin D
deficiency is common in young T1D patients [20], a condition that
may contribute to lower BMD and increases fracture risk [21,22].
While several evidences support the efficacy of vitamin D
supplementation at any age, no data are available in T1D patients
in terms of bone turnover and fracture prevention.
In addition, new research lines link bone metabolism to
pancreatic function. Thus, it has been shown that osteocalcin
(OC), an osteoblast-derived protein, has endocrine effects acting
on islet cells by stimulating b-cell proliferation and insulin
secretion [23,24]. As an insulin secretagogue, OC stimulates the
expression of insulin genes [24,25]. These findings have been
partially confirmed in humans, showing an inverse correlation
between OC and glucose homeostasis [26]. However, no data are
available in young T1D patients on OC and its effect on
parameters of b-cell function.
Therefore, we conducted a post-hoc analysis using sera collected
in a previous clinical trial, aiming to investigate the effect of 1 year
calcitriol administration on b-cell function [12], on another
parameter, the bone turnover. Moreover, we also tested in the
same patients the relationship between OC and b-cell function in
patients with recent onset of T1D.
Materials and Methods
Ethic Statement
This study was approved by the Ethical Committee at
University Campus Bio-Medico within the framework of the
IMDIAB investigators type 1 study, with informed consent signed
by patients or parents, where appropriate.
Patients
A post-hoc analysis was conducted using clinical data and serum
samples from a previous study [12]. Patients’, clinical manage-
ment, randomization strategy and guidelines for insulin therapy
were already published elsewhere [12]. Briefly, 27 patients with
recent onset T1D were recruited in the metropolitan area of Rome
by participating centers of the IMDIAB group. Patients’ inclusion
criteria included: (a) age at presentation between 10 and 35 years;
(b) duration of clinical disease (since the beginning of insulin
therapy) ,12 weeks; c) baseline C-peptide .0.25 nmol/l. In all
patients, presence of autoantibodies to glutamic acid decarboxyl-
ase (GAD) confirmed diagnosis of T1D. After baseline measure-
ments were completed and patients were blindly randomized to
receive either calcitriol (0.25 mg/daily) or placebo and followed up
for 1 year. All patients were treated with three injections of regular
insulin at meal times and one of basal insulin at bed time.
Evaluation of Bone Turnover
This was evaluated analyzing a marker of bone formation
(osteocalcin) and a marker of bone resorption (serum b-Cross-
Laps). Levels of osteocalcin and serum b-CrossLaps were
measured by EIA commercially available (ALPCO, USA). Serum
25-hydroxyvitamin D (25OHD) was measured by radioimmuno-
assay (Diasorin).
Pancreatic Function
Fasting plasma C-peptide was evaluated to establish the degree
of residual b-cell function and measured after euglycaemia was
achieved by chemiluminescence on ADVIA Centaur analyzer, a
two-site sandwich immunoassays using direct chemiluminescent
technology. The reference range of fasting C-peptide established
in 150 control subjects (71 females and 79 males matched for age
and with no family history of T1D) was 0.1–1.3 nmol/l with intra-
and inter-assay coefficient of variability between 10 and 15%,
respectively.
Statistical Analysis
Results are expressed as the mean 6 SE and P,0.05 was
considered statistically significant. The association between clinical
variables with parameters of bone turnover and vitamin D were
evaluated by simple correlation. Differences between means of the
two groups were compared by unpaired t-test and non-parametric
Mann–Whitney U-test, where applicable. Multiple comparison by
ANOVA was used to compare treatment groups across time
points. Data were analysed using SPSS (Chicago, IL, USA).
Results
We analyzed bone turnover in 27 T1D patients (,12 weeks
duration). Clinical features of patients are reported in Table 1.
At baseline, no significant differences were found in terms of age
and BMI between males and females. OC levels were significantly
lower in female than in male patients (17.863.1 ng/ml vs.
43.966.9 ng/ml; P,0.01. Figure 1) while no other metabolic
parameters as HbA1c, C-peptide differed between genders.
Analyzing the whole group of patients, baseline OC levels were
negatively correlated to age (r =20.59, P=0.02. Figure 2) while
no significant correlations were found in relation to HbA1c, C-
peptide or insulin requirement. BMI was positively correlated to
age (r = 0.44, P,0.05) and to C-peptide (r = 0.58, P,0.001).
At 1 year follow-up, OC and b-CrossLaps levels did not change
significantly compared to diagnosis nor in the placebo not in the
calcitriol-treated group. No significant differences were observed
between calcitriol and placebo groups for OC (37.2611.8 ng/ml
vs 25.867.4 ng/ml; P=0.39) and b-CrossLaps (0.3360.07 ng/ml
vs 0.5060.12 ng/ml; P=0.29) (table 2).
No significant correlations were found at 12 months in the
placebo group between OC and parameters of metabolic control,
such as HbA1c, C-peptide or insulin requirement. Changes in any
metabolic parameters across time were unrelated to OC levels.
Discussion
The natural history of diabetes is related to long term
complications that impact life quality and expectancy. The
skeleton is an important target of diabetes complications and
T1D patients exhibit bone loss and increased risk of fracture
compared with healthy age-matched subjects [2]. Because T1D
typically occurs in young age, the disruption in bone homeostasis
affects bone accrual and peak of bone mass. A metanalysis
confirmed the deleterious impact of T1D on bone health, showing
a lower Z-score at lumbar spine and at proximal femur in patients
with T1D compared to healthy subjects and consequent increased
risk of hip fracture (RR=6.94) [3].
The potential effect of calcitriol on bone turnover in T1D has
not been fully evaluated. Administration of pharmacological doses
of calcitriol in NOD mice showed a near two-fold increase of
osteocalcin levels [9]. According to our knowledge, this is the first
study assessing the effect of calcitriol supplementation on bone
turnover in T1D patients. In this study 12 month intervention with
the active form of vitamin D was not effective in modifying bone
turnover markers.
Calcitriol in Type 1 Diabetes
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To date, there are no available trials investigating the effect of
calcitriol on bone metabolism in new diagnosed T1D young
patients. Intervention studies conducted in adults and post-
menopausal women have yielded variable results, ranging from
no effective to a reduction of bone turnover [27]. Contrasting
findings have been reported also by studies with vitamin D3,
especially in young people and adolescents. Schou et al. have
shown that vitamin D supplementation in healthy children did not
affect bone turnover significantly [28]. Conversely, another study
on young subjects treated with D3 showed that, similarly to an
antiresorptive agent, vitamin D lowers primarily bone resorption
[18].
This is also the first study to evaluate the association between
OC levels and pancreatic function in T1D patients. Although
limited by the small sample size, our results might suggest that
metabolic action of OC is not relevant for controlling b-cell
function in T1D. To date, few human studies explored the
relationship between OC and glucose homeostasis and most of
these were conducted in healthy subjects or in patients with type 2
diabetes (T2D) and limited by the cross-sectional design. OC levels
have been reported to be lower in T2D compared to healthy
subjects [29], inversely related to body mass index, fat mass, and
plasma glucose [30,31,32,33]. Our data follow a different trend,
showing a lack of association between OC and b-cell function.
Although human studies in patients with T2D and in animals
support a positive feedback between osteoblast and b-cells, we may
speculate that in a condition of continuous autoimmune damage
against b-cells such as in T1D, the OC may be uneffective on
controlling b-cell function. The relationship between OC and
metabolic control in T1D subjects has been also investigated in a
recent cross-sectional study by Thrailkill et al. [34]. In contrast to
our findings, Thraikill et al. reported on a positive effect of OC on
endogenous insulin production (assessed by authors as C-peptide/
glucose ratio) [34], but several differences in term of sample size,
population (new-onset vs. long-standing diabetes), design of the
study (longitudinal vs. cross-sectional) and measure of endogenous
insulin production (C-peptide vs. C-peptide/glucose ratio) limit
the comparison between our study and the one conducted by
Thraikill. In our study, OC levels were lower in females than
males. This difference has been shown in healthy subjects, as a
consequence of the effect of sex hormones on skeletal tissues
during late-pubertal and post-pubertal stages [35,36]. Other
studies reproduced this difference also among young patients with
T1D [37,38]. Although OC levels are physiologically lower in
females than males, we cannot exclude that diabetes-induced
osteoblast disruption might amplify the difference we reported
[39].
The significance of our findings may be limited by the lack of
BMD measurements and the under-carboxylated osteocalcin
(ucOC) dosage. However, a large body of clinical evidence
suggests that total OC correlates to glucose homeostasis [26]
similarly to ucOC [31,40]. Moreover, although we did not
Table 1. Clinical and biochemical features of the study population at baseline.
Placebo group (n=15) Calcitriol group (n =12)
Males [n(%)] 8 (53) 8 (66)
Age [yrs] 22.0062.34 22.8362.14
BMI [kg/m2] 22.0760.62 22.5661.53
C-peptide [nmol/l] 0.3360.47 0.4460.71
HbA1c [%] 8.5660.38 9.6060.90
Insulin Requirement [U/Kg/die] 0.4060.03 0.4260.03
25OHD [ng/ml] 26.7863.80 24.0262.61
Data are mean 6 SE.
doi:10.1371/journal.pone.0056488.t001
Figure 1. Osteocalcin levels at baseline according to gender.
Osteocalcin levels were significantly higher in males than females
(P,0.01).
doi:10.1371/journal.pone.0056488.g001
Figure 2. Correlation between osteocalcin levels and age in
type 1 diabetes subjects at diagnosis. Baseline OC levels were
negatively correlated to age (r =20.59, P= 0.02). Dashed curves denote
upper and lower 95% confidence intervals.
doi:10.1371/journal.pone.0056488.g002
Calcitriol in Type 1 Diabetes
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measure serum levels of calcitirol, the same dosage was used by
Walter et al. who shown significant raise of calcitiol serum
concentrations in T1D after 9 months of treatment [41]. Finally,
given the limited number of studied subjects and the post-hoc nature
of the study, we cannot definitely rule out from this study the
interplay between OC and pancreatic function in T1D patients
and further studies, in larger cohorts of patients, are required.
In conclusion, the results of this study indicate that supplemen-
tation with 0.25ug calcitriol per day to patients with new-onset
T1D does not affect circulating markers of bone turnover.
However, larger ad-hoc trials with vitamin D investigating bone
turnover and fracture outcomes in T1D are needed. OC levels
were unrelated to b-cell function and other metabolic parameters
suggesting that OC is ineffective to control pancreatic function in
presence of aggressive autoimmune destruction. To disentangle
the role of OC in T1D more studies are needed, with larger
cohorts and longer follow-up.
Acknowledgments
Calcitriol and placebo tablets were prepared by Pharmacist Dr Raffaele
Marzano who is greatly acknowledged for his contribution.
Investigators of the IMDIAB group are: Anguissola GB, Astorri E,
Barchetta I, Benevento D, Beretta Anguissola G, Bizzarri C, Buzzetti R,
Capizzi M, Cappa M, Cassone Faldetta MR, Cavallo MG, Cipolloni L,
Cipponeri E, Crino` A, Di Stasio E, Fioriti E, Ghirlanda G, Guglielmi C,
Lauria A, Maggi D, Manfrini S, Matteoli MC, Maurizi AR, Moretti C,
Napoli N, Palermo A, Pitocco D, Portuesi R, Pozzilli P, Spera S, Strollo R,
Tuccinardi D, Valente L, Visalli N.
Author Contributions
Conceived and designed the experiments: PP. Analyzed the data: NN RS
CB DP. Contributed reagents/materials/analysis tools: CB DP DM SM
AS. Wrote the paper: NN RS EM.
References
1. Albright F (1948) A page out of the history of hyperparathyroidism. J Clin
Endocrinol Metab 8: 637–657.
2. Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients
with diabetes mellitus. J Bone Miner Res 22: 1317–1328.
3. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in
patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos Int 18:
427–444.
4. McCabe LR (2007) Understanding the pathology and mechanisms of type I
diabetic bone loss. J Cell Biochem 102: 1343–1357.
5. Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, et al. (2005) Bone
formation is impaired in a model of type 1 diabetes. Diabetes 54: 2875–2881.
6. Thrailkill KM, Lumpkin CK, Jr., Bunn RC, Kemp SF, Fowlkes JL (2005) Is
insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.
Am J Physiol Endocrinol Metab 289: E735–745.
7. Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes.
Diabetologia 48: 1247–1257.
8. Bock G, Prietl B, Mader JK, Holler E, Wolf M, et al. (2011) The effect of vitamin
D supplementation on peripheral regulatory T cells and beta cell function in
healthy humans: a randomized controlled trial. Diabetes Metab Res Rev 27:
942–945.
9. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of
autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia
37: 552–558.
10. (1999) Vitamin D supplement in early childhood and risk for Type I (insulin-
dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group.
Diabetologia 42: 51–54.
11. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of
vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358: 1500–
1503.
12. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, et al. (2010) No
protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes:
the IMDIAB XIII trial. Diabetes Care 33: 1962–1963.
13. Lehtonen-Veromaa MK, Mottonen TT, Nuotio IO, Irjala KM, Leino AE, et al.
(2002) Vitamin D and attainment of peak bone mass among peripubertal
Finnish girls: a 3-y prospective study. Am J Clin Nutr 76: 1446–1453.
14. Rizzoli R, Bianchi ML, Garabedian M, McKay HA, Moreno LA (2010)
Maximizing bone mineral mass gain during growth for the prevention of
fractures in the adolescents and the elderly. Bone 46: 294–305.
15. Winzenberg T, Powell S, Shaw KA, Jones G (2011) Effects of vitamin D
supplementation on bone density in healthy children: systematic review and
meta-analysis. BMJ 342: c7254.
16. El-Hajj Fuleihan G, Nabulsi M, Tamim H, Maalouf J, Salamoun M, et al.
(2006) Effect of vitamin D replacement on musculoskeletal parameters in school
children: a randomized controlled trial. J Clin Endocrinol Metab 91: 405–412.
17. Zamora SA, Rizzoli R, Belli DC, Slosman DO, Bonjour JP (1999) Vitamin D
supplementation during infancy is associated with higher bone mineral mass in
prepubertal girls. J Clin Endocrinol Metab 84: 4541–4544.
18. Viljakainen HT, Natri AM, Karkkainen M, Huttunen MM, Palssa A, et al.
(2006) A positive dose-response effect of vitamin D supplementation on site-
specific bone mineral augmentation in adolescent girls: a double-blinded
randomized placebo-controlled 1-year intervention. J Bone Miner Res 21: 836–
844.
19. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, et al. (1993) Bone
density at various sites for prediction of hip fractures. The Study of Osteoporotic
Fractures Research Group. Lancet 341: 72–75.
20. Pozzilli P, Manfrini S, Crino A, Picardi A, Leomanni C, et al. (2005) Low levels
of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly
diagnosed type 1 diabetes. Horm Metab Res 37: 680–683.
21. Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, et al. (2008) Serum
25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med
149: 242–250.
22. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
23. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially
regulates beta cell and adipocyte gene expression and affects the development of
metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 105: 5266–5270.
24. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al. (2007) Endocrine
regulation of energy metabolism by the skeleton. Cell 130: 456–469.
25. Ducy P (2011) The role of osteocalcin in the endocrine cross-talk between bone
remodelling and energy metabolism. Diabetologia 54: 1291–1297.
26. Motyl KJ, McCabe LR, Schwartz AV (2010) Bone and glucose metabolism: a
two-way street. Arch Biochem Biophys 503: 2–10.
27. Peppone LJ, Hebl S, Purnell JQ, Reid ME, Rosier RN, et al. (2010) The efficacy
of calcitriol therapy in the management of bone loss and fractures: a qualitative
review. Osteoporos Int 21: 1133–1149.
28. Schou AJ, Heuck C, Wolthers OD (2003) Vitamin D supplementation to healthy
children does not affect serum osteocalcin or markers of type I collagen turnover.
Acta Paediatr 92: 797–801.
29. Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, et al. (2006) Evaluation of
bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl
Med Assoc 98: 1598–1604.
30. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, et al.
(2009) Serum osteocalcin level is associated with glucose metabolism and
Table 2. Biochemical markers of bone turnover during the trial.
Baseline 12 months
Placebo group Calcitriol group Placebo group Calcitriol group
Osteocalcin [ng/ml] 34.6967.04 33.4967.91 25.867.35 37.19611.77
b-CrossLaps [ng/ml] 0.7760.14 0.5560.17 0.5060.12 0.3460.08
Data are mean 6 SE.
doi:10.1371/journal.pone.0056488.t002
Calcitriol in Type 1 Diabetes
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e56488
atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab
94: 45–49.
31. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, et al.
(2011) Serum undercarboxylated osteocalcin was inversely associated with
plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:
187–194.
32. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, et al. (2009)
Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly
Swedish men. J Bone Miner Res 24: 785–791.
33. Zhou M, Ma X, Li H, Pan X, Tang J, et al. (2009) Serum osteocalcin
concentrations in relation to glucose and lipid metabolism in Chinese
individuals. Eur J Endocrinol 161: 723–729.
34. Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Lumpkin CKJ, et al. (2011)
Determinants of undercarboxylated and carboxylated osteocalcin concentrations
in type 1 diabetes. Osteoporos Int DOI 10.1007/s00198-011-1807-7.
35. Fares JE, Choucair M, Nabulsi M, Salamoun M, Shahine CH, et al. (2003)
Effect of gender, puberty, and vitamin D status on biochemical markers of bone
remodedeling. Bone 33: 242–247.
36. Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone
turnover in children and adolescents. Osteoporos Int 11: 281–294.
37. Pater A, Sypniewska G, Pilecki O (2010) Biochemical markers of bone cell
activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 23:
81–86.
38. Brandao FR, Vicente EJ, Daltro CH, Sacramento M, Moreira A, et al. (2007)
Bone metabolism is linked to disease duration and metabolic control in type 1
diabetes mellitus. Diabetes Res Clin Pract 78: 334–339.
39. Leger J, Marinovic D, Alberti C, Dorgeret S, Chevenne D, et al. (2006) Lower
bone mineral content in children with type 1 diabetes mellitus is linked to female
sex, low insulin-like growth factor type I levels, and high insulin requirement.
J Clin Endocrinol Metab 91: 3947–3953.
40. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, et al. (2012) Serum
undercarboxylated osteocalcin levels are inversely associated with glycemic
status and insulin resistance in an elderly Japanese male population: Fujiwara-
kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int 23: 761–770.
41. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, et al. (2010) No effect of
the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin
requirement in adults with new-onset type 1 diabetes. Diabetes Care 33: 1443–
1448.
Calcitriol in Type 1 Diabetes
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e56488
